People · Operator
Named in public records as an officer, director or promoter · active 2020–2021 · Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CARISMA Therapeutics Inc. | — | Biotechnology | Series C | $95.0M | $1.3B | 2020 |
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $427.0M | 2021 |
| Clene Inc. | — | Pharmaceuticals | Series A | $16.6M | $33.6M | 2021 |
Chidozie Ugwumba at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chidozie Ugwumba on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Briggs Morrison | 1 | 8 |
| John Stevens | 1 | 6 |
| Michael Heffernan | 1 | 5 |
| Peter Finn | 1 | 5 |
| Mark McDade | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Richard Murray | 1 | 5 |
| Michael Poisel | 1 | 4 |
| David Matlin | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Margarita Chavez | 1 | 4 |
| Steven Kelly | 1 | 4 |
| Shalom Jacobovitz | 1 | 3 |
| Alison Mosca | 1 | 2 |
| Reed Wilcox | 1 | 2 |
| Philip Reilly | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Regina Hodits | 1 | 2 |
| Jonathon Gay | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.